Abstract
Abstract
Objective
To investigate the relation between interleukin-6 concentration and oxidative status of HIV infected patients with or at risk of Kaposi’s disease in Yaoundé.
Methods
We conducted a two-months cross-sectional study on 87 consenting HIV infected patients followed at the Day Hospital of the Yaoundé Central Hospital. Serum/plasma obtained after centrifugation of blood collected in dry/EDTA tubes was used for the determination of Human Herpes Virus-8 antigen (HHV-8) and Interleukin-6 (IL-6) by the ELISA technique, and that of oxidative stress markers: Malondialdehyde (MDA) reduced Glutathione (GSH) and total antioxidant capacity by spectrophotometry.
Results
Subjects belonging to the [40–50[year-old age group were mainly represented in our study population with 43.7%. The average age was 44.6 ± 10.4 years with extremes ranging from 26 to 72 years. The sex ratio was 0.24. Our population was mainly represented by people infected with HIV type I (90.8%) and 3.4% had developed clinical signs of Kaposi’s disease. The prevalence of the HHV-8 antigen was 57.5%. Immune and oxidative parameters did not vary with age, sex and therapeutic line. We noted a significant increase in IL-6 concentrations in patients positive to the HHV-8 antigen for IL-6 concentrations < 37 (P = 0.005; CI= [0.40; 0.59]. MDA and GSH concentrations increased significantly with the HHV-8 infection (P < 0.0001; CI= [0.40; 0.59] and P < 0.0001; CI= [13.30;21.45], respectively). Total antioxidant capacity (FRAP) decreased significantly with HHV-8 infection (P = 0.004; CI= [-69.18; -13.78]). We noted a significant increase in MDA concentrations in patients taking their ARVs irregularly, (P < 0.0001).
Conclusion
Our study showed a weak positive correlation between IL-6 and MDA, a strong negative correlation between FRAP and MDA and a strong positive correlation between MDA and GSH highlighting the association of these few markers of oxidative stress and Il-6 to the risk of Kaposi’s disease.
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Virology
Reference28 articles.
1. Radu O, Pantanowitz L. Kaposi Sarcoma. Arch Pathol Lab Mesd 31 janv. 2013;137(2):289–94.
2. Schneider JW, Dittmer DP. Diagnosis and treatment of Kaposi Sarcoma. Am J Clin Dermatol août. 2017;18(4):529–39.
3. Boué F, Lebbé C. Le sarcome de Kaposi. Bull Cancer (Paris). 2003;90(5):393–8.
4. Aubry PP. Maladie de Kaposi Actualités 2019.:5.
5. NDOUMA AG. Maladie de Kaposi stomatologique chez les personnes vivant avec le VIH/Sida:étude de 12 cas observés à Yaoundé [Internet]. HEALTH SCIENCES AND DISEASE. ; 2014 [cité 19 mai 2020]. Disponible sur: https://www.hsd-fmsb.org/index.php/hsd/thesis/view/192